- Home
- IRMD vs AVTX Comparison
IRMD vs AVTX Comparison
Compare IRMD & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IRMD | AVTX |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 956.7M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IRMD | AVTX |
|---|---|---|
| Price | $94.78 | $18.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $116.00 | $40.57 |
| AVG Volume (30 Days) | 113.2K | ★ 1.5M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | 16.67 | ★ 72.07 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $83,814,000.00 | $27,813,137.00 |
| Revenue This Year | $12.38 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | $208.58 | ★ N/A |
| Revenue Growth | 14.43 | ★ 2312.27 |
| 52 Week Low | $56.20 | $6.21 |
| 52 Week High | $107.90 | $24.27 |
Technical Indicators
Market Signals| Indicator | IRMD | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 51.08 |
| Support Level | $90.12 | $17.32 |
| Resistance Level | $97.63 | $19.06 |
| Average True Range (ATR) | 3.12 | 1.17 |
| MACD | -0.51 | -0.22 |
| Stochastic Oscillator | 30.51 | 18.81 |
Price Performance
Historical ComparisonAbout IRMD iRadimed Corporation
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.